MedTrace Logo

A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis

NCT03347370 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 626

Last updated 2019-09-25

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety of subcutaneous (SC) interferon beta therapies with regard to frequency of injection site reactions (ISR) and flu-like symptoms (FLS) as reported by the relapsing-remitting multiple sclerosis (RRMS) participants.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

SC Peginterferon beta-1a

All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).

DRUG

SC interferon beta-1a

All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).

DRUG

SC interferon beta-1b

All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product.

Sponsors & Collaborators

  • AMS Advanced Medical Services GmbH

    collaborator INDUSTRY

  • Biogen

    lead INDUSTRY

Principal Investigators

  • Medical Director · Biogen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-27
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03347370 on ClinicalTrials.gov